Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

apceth Received the Second Round of Funding for Its Innovative Stem Cell-Based Cancer Therapeutic

Published: Wednesday, February 06, 2013
Last Updated: Wednesday, February 06, 2013
Bookmark and Share
Development of apceth’s first innovative “Advanced Therapy Medicinal Product” based on modified adult stem cells for cancer therapy.

As of January 2013 apceth has entered the second round of funding for the development of its first cancer therapeutic based on patient’s own modified adult mesenchymal stem cells (MSC) running under the portfolio name Agenmestencel-T.

In December 2012 apceth has successfully concluded the first 2.5-year round of funding through the Federal Ministry of Education and Research (BMBF) for the development of Agenmestencel-T as part of the Munich Biotech Cluster initiative “m4 Personalized Medicine and Targeted Therapies” (Cluster project PM5, FKZ: 16EX1021K).

The Munich Biotech Cluster comprises a rich network of biotech and pharma companies, research institutions and clinical centers in order to promote and expedite the creation of the future orientated personalized and targeted therapy strategies. As the winner of the second round of the “Leading-Edge Cluster Competition” in 2010 the Munich Biotech Cluster has at its disposal a considerable funds granted by BMBF and the Bavarian Government within its “m4 Personalized Medicine and Targeted Therapies” initiative for this ambitious aim.

The second round of funding through BMBF apceth was granted at the end of 2012 as part of the m4 Cluster initiative. With this apceth’s total approved budget for the development of Agenmestencel-T amounted to 4.7 million € within a period of less than five years between July 2010 and March 2015.

Agenmestencel-T is a highly innovative stem cell-based medicinal product for personalized therapy of advanced and/or metastatic cancers. With Agenmestencel-T apceth is committed to provide a novel cell-based cancer drug which will be custom-made for every single patient. Combining the stringent principles of pharmaceutical development with targeted biomarker-based strategies for patient stratification, apceth aims to create the cancer drugs of uppermost quality and safety, while identifying those cancer patients that can mostly benefit from this novel cell therapy.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

apceth’s First-In-Man, First-In-Class Clinical Trial with MSCs is Now Enrolling
TREAT ME Phase I/II clinical trial for patients suffering from advanced adenocarcinoma of the gastro-intestinal tract.
Monday, January 27, 2014
apceth Names Dr Stefanos Theoharis Chief Business Officer
Dr Stefanos Theoharis will lead apceth’s business development and business operations and promote the continued expansion of apceth’s GMP manufacturing business.
Thursday, September 05, 2013
apceth Receives Approval for a Clinical Cancer Trial with Adult Mesenchymal Stem Cells
apceth's first innovative cellular anti-cancer drug based on modified mesenchymal stem cells enters Phase I / II of clinical testing.
Friday, June 14, 2013
apceth Received Extended Manufacturer's Licence for Somatic Cell Therapeutics at the Ottobrunn Site
Four new cleanrooms expand capacity to a total of 600 m2.
Tuesday, November 01, 2011
apceth Extends Top Management
Prof. Ralf Huss, previously Global Head of the Therapeutic Cell Initiative at Roche, joins the management board of apceth GmbH & Co. KG, Munich.
Monday, October 10, 2011
apceth Starts First Phase I/II Clinical Study on Somatic Cell Therapy for pAOD
Study investigates tolerability and efficacy of apceth's somatic cell therapeutics for treatment of pAOD after angioplasty.
Tuesday, August 23, 2011
apceth is Granted a Manufacturer's Licence for Somatic Cell Therapy
Manufacturer's licence enables contract manufacture and development of innovative cell preparations for contractual partners.
Tuesday, August 09, 2011
Scientific News
Nanosensors Could Determine Tumours’ Ability to Remodel Tissue
Researchers design nanosensors that can profile tumours, focusing on protease levels.
1960s Antibiotics Show Promise for TB Therapy
Research suggests antibiotics introduced in 1963 to treat bacterial infections show promise for tuberculosis therapy.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Studies Explore the Science of Cardiovascular Diseases
Two studies highlight how basic science research insights are key to future treatment breakthroughs.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Using Stem Cells to Grow a 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
MRI Guidance Aids Stem Cell Delivery
Scientists have delivered stem cells to the brain with unprecedented precision, infusing the cells under real-time MRI guidance.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!